Compare Hilton Hotels Corporation Common Stock (HLT) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Twist Bioscience Corp — how do they compare? Hilton Hotels Corporation Common Stock trades at $326.56 (market cap $72.76B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 7.2× Twist Bioscience Corp's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 138 Days and Twist Bioscience Corp for 27 Days on average.
| HLT | TWST | |
|---|---|---|
Market Cap | $72.76B | $10.08B |
Volume | 1,148,634 | 4,229,037 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $205.00 |
52-Week Low | $256.96 | $25.45 |
Typical Hold Time | 138 Days | 27 Days |
Enterprise Value | $85.78B | $10.01B |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $326.56, up 1.89% with a bullish technical outlook. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth has been steady, reaching $12.04B in 2025, though valuation multiples like P/E of 47.47 appear elevated. Analyst consensus is strongly positive with 57% buy ratings and a $348.11 price target, while institutional investors have been increasing positions.
The outlook remains favorable given Hilton's strong brand positioning and global travel recovery, but risks include high debt levels and sensitivity to economic cycles. With technical indicators bullish and fundamental growth intact, HLT offers growth potential though current valuation requires careful monitoring of earnings delivery.
Twist Bioscience (TWST) trades at $159.78, up 2.65% today, showing strong momentum despite mixed technical signals. The company continues to demonstrate robust revenue growth, with 2025 revenue reaching $377 million, though profitability remains elusive with a -31.66% net income margin. Recent positive developments include a strategic partnership with Eli Lilly's TuneLab AI platform announced September 16, 2026, driving investor optimism about the company's AI-driven drug discovery capabilities.
While analyst consensus remains bullish with 73% buy ratings, the stock faces significant fundamental challenges including persistent cash burn and negative earnings. The current price exceeds the $145.20 consensus target, suggesting limited near-term upside. Key risks include execution challenges in achieving profitability and dependence on AI partnerships for growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
